Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Curaleaf Holdings (TSX:CURA) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Curaleaf Holdings Net Margin % Related Terms
Curaleaf Holdings Net Margin % Historical Data
* Premium members only.
The historical data trend for Curaleaf Holdings's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Curaleaf Holdings's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Curaleaf Holdings Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Curaleaf Holdings's Net Margin % distribution charts can be found below:
* The bar in red indicates where Curaleaf Holdings's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Curaleaf Holdings (TSX:CURA) has a Net Margin % of 3.68% as of Jun. 2026. Net margin is the ratio of total net income to net sales. View historical data on Curaleaf Holdings and its competitors. According to the industry distribution chart, Curaleaf Holdings ranks #690 out of 958 companies in the Drug Manufacturers industry, placing it in the top 72%.
Is Curaleaf Holdings' Net Margin % too high?
Curaleaf Holdings' current Net Margin % is 3.68%. The Drug Manufacturers industry median Net Margin % is 5.60. Curaleaf Holdings' value of 3.68% is 34.2% below this industry median. Based on the distribution chart, Curaleaf Holdings ranks #690 out of 958 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Curaleaf Holdings has a GF Score™ of 75/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Curaleaf Holdings' Net Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Curaleaf Holdings ranks #690 out of 958 companies for Net Margin %. This places Curaleaf Holdings in the lower half of its industry. The industry median Net Margin % is 5.60. Curaleaf Holdings' value of 3.68% is 34.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.60, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Curaleaf Holdings's current Net Margin % of 3.68% is 34.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Curaleaf Holdings and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Curaleaf Holdings's current Net Margin % is 3.68%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Curaleaf Holdings stock overvalued right now?
Based on GuruFocus' analysis, Curaleaf Holdings (TSX:CURA) is currently considered Modestly Overvalued. The stock's GF Value™ is C$11.59, compared to a current price of C$13.22 — trading 14.1% above its estimated fair value. The current Net Margin % is 3.68% and 34.2% below the Drug Manufacturers industry median of 5.60. Curaleaf Holdings' overall GF Score™ is 75/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Curaleaf Holdings (TSX:CURA), the current Net Margin % is 3.68% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Curaleaf Holdings (TSX:CURA) Overvalued in 2026?
Based on GuruFocus' analysis, Curaleaf Holdings stock appears to be overvalued.
The current stock price of C$13.22 is trading 14.1% above its estimated GF Value™ of C$11.59.
GuruFocus considers Curaleaf Holdings to be Modestly Overvalued.
Key valuation signals for TSX:CURA:
Net Margin %: 3.68%
GF Value™: C$11.59 vs. price of C$13.22 (14.1% above fair value)
Industry Position: 34.2% below the Drug Manufacturers median (#690 of 958)
No single metric tells the full story. See the TSX:CURA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Curaleaf is headquartered in Wakefield, Massachusetts, and cultivates and sells medicinal and recreational cannabis in the US. The company has operations in 17 states. Its brands include Curaleaf, Select, and Grassroots. The company has made acquisitions that give it exposure to the growing European market, a unique feature among US multistate operators.
75GF Score
Get the complete analysis for TSX:CURA
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSX:CURA has been successfully added to your 
